Analysts Offer Predictions for CymaBay Therapeutics Inc.’s Q4 2017 Earnings (NASDAQ:CBAY)
CymaBay Therapeutics Inc. (NASDAQ:CBAY) – Stock analysts at Oppenheimer Holdings dropped their Q4 2017 earnings estimates for shares of CymaBay Therapeutics in a research report issued on Friday. Oppenheimer Holdings analyst J. Olson now anticipates that the biopharmaceutical company will earn $0.03 per share for the quarter, down from their previous forecast of $0.07. Oppenheimer Holdings currently has a “Outperform” rating and a $15.00 target price on the stock.
A number of other equities analysts have also issued reports on CBAY. Ifs Securities lowered CymaBay Therapeutics from a “strong-buy” rating to an “outperform” rating in a report on Friday. BidaskClub lowered CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 3rd. Piper Jaffray Companies restated an “overweight” rating and issued a $12.00 target price on shares of CymaBay Therapeutics in a research report on Tuesday, July 25th. CIBC restated an “outperform” rating and issued a $15.00 target price (up from $8.00) on shares of CymaBay Therapeutics in a research report on Thursday, July 20th. Finally, Citigroup Inc. restated an “outperform” rating and issued a $15.00 target price (up from $8.00) on shares of CymaBay Therapeutics in a research report on Thursday, July 20th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. CymaBay Therapeutics has a consensus rating of “Buy” and an average price target of $11.88.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/14/analysts-offer-predictions-for-cymabay-therapeutics-inc-s-q4-2017-earnings-nasdaqcbay.html.
Shares of CymaBay Therapeutics (CBAY) opened at 6.57 on Monday. The firm’s 50-day moving average price is $6.53 and its 200-day moving average price is $4.38. The firm’s market capitalization is $188.90 million. CymaBay Therapeutics has a 52-week low of $1.15 and a 52-week high of $8.29.
CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.06.
Several hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in CymaBay Therapeutics by 0.8% in the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 140 shares during the last quarter. ClariVest Asset Management LLC bought a new stake in shares of CymaBay Therapeutics during the first quarter worth $105,000. LVM Capital Management Ltd. MI raised its stake in shares of CymaBay Therapeutics by 100.0% in the second quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 10,000 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of CymaBay Therapeutics during the first quarter worth $129,000. Finally, TFS Capital LLC bought a new stake in shares of CymaBay Therapeutics during the first quarter worth $169,000. 25.39% of the stock is owned by institutional investors.
In other CymaBay Therapeutics news, Director Robert James Wills purchased 5,000 shares of the business’s stock in a transaction on Tuesday, August 1st. The stock was purchased at an average price of $6.84 per share, for a total transaction of $34,200.00. Following the completion of the purchase, the director now directly owns 25,200 shares in the company, valued at $172,368. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Sujal Shah acquired 10,000 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were purchased at an average cost of $7.34 per share, with a total value of $73,400.00. Following the acquisition, the insider now owns 75,891 shares of the company’s stock, valued at approximately $557,039.94. The disclosure for this purchase can be found here. Insiders have acquired 20,000 shares of company stock valued at $144,750 over the last 90 days. Corporate insiders own 15.10% of the company’s stock.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.